Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium–glucose cotransporter 2 (SGLT2) inhibitors (1). This Communication was based on 20 clinical cases requiring...

Abstract Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and admission rates for heart failure (HF). However, the mechanisms behind these benefits are not fully understood. This study was performed to investigate effects of SGLT-2i dapagliflozin on whole body i...

Background and Aim: The occurrence of urinary tract infection (UTI) in type 2 diabetes (T2DM) administered with sodium-glucose co-transporter-2 (SGLT2) inhibitors are still debatable. present study aimed to assess the UTI T2DM patients taking SGLT-2 regulate their blood sugar levels. Patients Methods: This cross-sectional was carried out on 369 investigated Nephrology division Khyber Teaching H...

We are thankful for the comments on ‘Sodium glucose co-transporter (SGLT2) inhibitor: Patient safety and clinical importance’, and we appreciate the concern raised for its risk of euglycemic diabetic ketoacidosis (DKA). During clinical development programs for a new drug approval, it is not uncommon that some unexpected safety issues may go unobserved. Interestingly, the incidence of ketoacidos...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become increasingly prescribed because of their proven protective effects on the heart and kidneys, carbohydrate-restricted diets are popular therapeutic approaches for patients with obesity diabetes. A 28-year-old obese woman recently diagnosed diabetes developed euglycemic diabetic ketoacidosis (DKA) while dapagliflozin, an SGLT2 inhibito...